ResearcherIsalaNo recent work listed

Tonke L. de Jong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0137-2431; OpenAlex author ID A5082819135. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper

Papers 1

Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101909 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Floris A. Vuijk · 1 shared paper, 2023 · strength 0.16
- Paper Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable… DOI 10.1016/j.suronc.2023.101909 ↗
Gijs A. Patijn · 1 shared paper, 2023 · strength 0.16
- Paper Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable… DOI 10.1016/j.suronc.2023.101909 ↗
Vincent B. Nieuwenhuijs · 1 shared paper, 2023 · strength 0.16
- Paper Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable… DOI 10.1016/j.suronc.2023.101909 ↗
J. Sven D. Mieog · 1 shared paper, 2023 · strength 0.16
- Paper Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable… DOI 10.1016/j.suronc.2023.101909 ↗
Alexander L. Vahrmeijer · 1 shared paper, 2023 · strength 0.16
- Paper Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable… DOI 10.1016/j.suronc.2023.101909 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.